Analysis of Defined Elements on DXA in Patients Undergoing Hip Arthroplasty
Launched by I.R.C.C.S OSPEDALE GALEAZZI-SANT'AMBROGIO · Mar 14, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how certain imaging techniques can help doctors understand changes in bone health around the hip area after hip replacement surgery, also called hip arthroplasty. Researchers are looking at two specific measurements: bone mineral density (BMD), which tells us how strong the bone is, and the Bone Strain Index (BSI), which shows how much stress the bone can handle. By tracking these measurements over time, starting right after surgery and then again at six months, the study aims to see how the bones around the new hip joint change during recovery.
To participate in this trial, you need to be between 50 and 90 years old and scheduled for hip replacement surgery due to conditions like arthritis or hip joint deformities. The study is open to both men and women, but you should not have any serious infections, certain health conditions, or be taking specific medications that could affect your bone health. If you join the trial, you can expect to have your bone health monitored before and after your surgery, helping researchers learn more about how to improve outcomes for future patients undergoing similar procedures.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients who are candidates for elective hip arthroplasty surgery (indication determined only by the Orthopedic Surgeon)
- • Patients with noninflammatory degenerative hip joint disease, including osteoarthritis and the outcomes of congenital hip dysplasia.
- • Hip joint deformity correction surgery
- • Patients aged 50 to 90 years (completed)
- • 18 ≤ Body Mass Index (BMI) ≤ 35 kg/m2
- • Postmenopausal women (absence of menstrual cycle for at least 2 years)
- • Willingness and ability to provide informed consent
- Exclusion Criteria:
- • Taking drugs that may interfere with muscle or bone metabolism,
- • Evidence of diseases known to interfere with bone or muscle metabolism
- • Rheumatoid arthritis
- • Patients undergoing revision hip replacement surgery
- • Presence of infection or suspicion of infection at the hip
- • Inability to provide informed consent
- • Previous synthetic surgery for proximal femur fractures
- • Severe obesity (BMI \>35kg/m2)
About I.R.C.C.S Ospedale Galeazzi Sant'ambrogio
The I.R.C.C.S. Ospedale Galeazzi-Sant'Ambrogio is a leading clinical research institute and hospital in Italy, renowned for its commitment to advancing medical science through innovative research and high-quality patient care. As a designated Institute of Hospitalization and Care of Scientific Relevance (I.R.C.C.S.), it focuses on translational research that bridges the gap between laboratory findings and clinical applications. The facility is equipped with state-of-the-art technology and a multidisciplinary team of experts, enabling it to conduct a wide range of clinical trials aimed at improving treatment outcomes across various medical fields. Its dedication to ethical practices and patient safety ensures that all research activities align with the highest international standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Milan, , Italy
Patients applied
Trial Officials
Laura Mangiavini
Principal Investigator
University of Milan, IRCCS Ospedale Galeazzi-Sant'Ambrogio
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported